Skip to Main Content

Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing decisions in the U.S. for multiple sclerosis drugs have been driven by other factors, especially what competitors are doing, according to four executives whose insights were described in a new paper.

Besides competition, the executives also cited overall corporate growth objectives, the ability to set U.S. prices higher than in other countries, and distortions caused by the complicated rebate system used to establish insurance reimbursement, the researchers reported in Neurology.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!